This report describes a case of neonatal bacteraemia and meningitis due to Streptococcus gallolyticus subsp. pasteurianus. Based on the identification kit results, this species may have been reported as Streptococcus bovis or S. bovis biotype II. The accurate identification of this organism is mandatory for evaluating the aetiology of neonatal meningitis.
Case report
A 5-day-old female was admitted to Fukuoka Red Cross Hospital. She was born at term, weighing 3192 g, and the culture of a maternal prenatal vaginal swab was negative for group B streptococcus. The labour was uneventful, without premature rupture of the membrane. The patient had a fever of 38.46C on the fourth day after birth. The results of blood examination revealed that there were 3600 leukocytes ml 21 and that the C-reactive protein level was less than 1 mg l 21 . The fever persisted the next day, and the patient was then admitted to the hospital. The patient's anterior fontanel bulged slightly, and her overall activity was poor. A sepsis work-up and lumbar puncture were performed. The results of the blood examination were as follows: 13 900 leukocytes ml 21 ; 12.8 g haemoglobin dl 21 ; 279 000 platelets ml 21 ; and 65 mg C-reactive protein l 21 . The cerebrospinal fluid was cloudy with 12 971 leukocytes ml 21 (12 800 polymorphonuclear cells ml 21 and 171 mononuclear cells ml 21 ). The cerebrospinal glucose level was 21 mg dl 21 and the protein level was 3.32 g dl 21 . No antigens for Haemophilus influenzae type b, Streptococcus pneumoniae, Neisseria meningitidis group A, B, or C, or E. coli K1 were detected (Slidex-Méningite-Kit5; bioMérieux) in the cerebrospinal fluid. Treatment with cefotaxime (200 mg?kg -1 per day), panipenem-betamipron (120 mg?kg -1 per day) and intravenous cglobulin (300 mg?kg -1 per day for 2 days) was started.
Cultures of both the cerebrospinal fluid and blood showed Gram-positive cocci, which were initially reported as Streptococcus species (non-enterococcus). The cerebrospinal fluid isolate was susceptible to penicillin G (MIC 0.06 mg ml 21 ), cefotaxime (MIC 0.06 mg ml 21 ) and imipenem (MIC ¡0.008 mg ml 21 ). Panipenem-betamipron treatment was discontinued, and treatment with cefotaxime alone continued for 14 days. Culture of the cerebrospinal fluid was negative on day 3 of hospitalization. Non-contrast head computed tomography scans, which were obtained on day 11 of hospitalization, revealed no intracranial haemorrhage or subdural abscess. The patient was discharged without sequelae.
The isolate possessed Lancefield's D antigen (Streptex; Remel). According to an API 20 Strep test (bioMérieux), the isolate was identified as S. bovis biotype II/2. Because the S. bovis complex has been recently reclassified (Schlegel et al., 2003 ; and see below), we tested for gallate hydrolysis (tannase) activity of the isolate according to the reference by Osawa et al. (1995) . Various biochemical activities of the isolate are described in Table 1 biotype II/2. S. bovis is delineated into two biotypes according to their ability (biotype I) or inability (biotype II) to ferment mannitol (Facklam, 1972; Parker & Ball, 1976) . S. bovis (biotype II) is further divided into biotypes II/ 1 and II/2 on the basis of phenotypic testing with the Rapid Strep system (bioMérieux) (Coykendall & Gustafson, 1985) . It has been well documented that S. bovis (biotype I) is associated with colonic neoplasia and bacterial endocarditis in adults (Ruoff et al., 1989; Herrero et al., 2002) . In contrast, S. bovis (biotype II) is associated with invasive infection in neonates and infants (Grant et al., 2000; Cheung et al., 2000; Gavin et al., 2003; Nagai et al., 2008) , as well as adult bacteraemia both in Western and Eastern countries (Clarridge et al., 2001; Lee et al., 2003) . Among the reported cases of neonatal invasive infection due to S. bovis (Gerber et al., 2006; Nagai et al., 2008) , S. bovis biotype II/2 was described in two cases (Gavin et al., 2003; Nagai et al., 2008) . No reports have described the aetiological organism of invasive infections as S. gallolyticus subsp. pasteurianus.
The taxonomic status of the S. bovis group has been evolving in the last few decades. Farrow et al. (1984) demonstrated that the S. bovis/Streptococcus equinus complex comprised six DNA groups. It was shown that S. bovis biotype II/2 belonged to the DNA group 2 of Farrow's classification (Schlegel et al., 2003; Poyart et al., 2002) . According to the biochemical characteristics, the members in this DNA group have been reclassified and renamed S. gallolyticus subsp. gallolyticus, S. gallolyticus subsp. pasteurianus or S. gallolyticus subsp. macedonicus (Schlegel et al., 2003) . These subspecies have similar 16S rRNA gene sequences and cannot be discriminated from each other solely by 16S rRNA gene sequence (Clarridge et al., 2001; Schlegel et al., 2003) . Instead, the aesculin-and gallate-hydrolysis activity measurement works for identifying these subspecies, though the latter is not included in the identification kit (Table 1) . According to the new classification, S. bovis biotype I and S. bovis biotype II/2 correspond to S. gallolyticus subsp. gallolyticus and S. gallolyticus subsp. pasteurianus, respectively (Schlegel et al., 2003) .
The isolate from our case was susceptible to penicillin G, cefotaxime and panipenem, and resistant to erythromycin and minocycline. Enterococcus spp. have phenotypic characteristics similar to those of S. gallolyticus subsp. pasteurianus, i.e. they are non-haemolytic, positive for Lancefield's D antigen and positive for aesculin hydrolysis. Penicillin G is considered to be an efficient treatment for neonatal infections caused by S. gallolyticus subsp. pasteurianus, while vancomycin and/or aminoglycosides may be considered for the treatment of neonatal infections caused by Enterococcus. Thus, the accurate identification of the isolate is crucial for selecting appropriate antibiotic therapy.
This report describes a case of neonatal bacterial meningitis due to S. gallolyticus subsp. pasteurianus. The importance of this organism as a causative agent of invasive infection in neonates should be emphasized.
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